A_DT
PMLRARalpha_NN
transgene_NN
initiates_VBZ
murine_JJ
acute_JJ
promyelocytic_JJ
leukemia_NN
._.

The_DT
malignant_JJ
cells_NNS
of_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
-LRB-_-LRB-
APL_NN
-RRB-_-RRB-
contain_VBP
a_DT
reciprocal_JJ
chromosomal_JJ
translocation_NN
that_WDT
fuses_VBZ
the_DT
promyelocytic_JJ
leukemia_NN
gene_NN
-LRB-_-LRB-
PML_NN
-RRB-_-RRB-
with_IN
the_DT
retinoic_JJ
acid_NN
receptor_NN
alpha_NN
gene_NN
-LRB-_-LRB-
RAR_NN
alpha_NN
-RRB-_-RRB-
._.

To_TO
test_VB
the_DT
hypothesis_NN
that_IN
the_DT
chimera_NN
PMLRAR_NN
alpha_NN
plays_VBZ
a_DT
role_NN
in_IN
leukemogenesis_NN
,_,
we_PRP
expressed_VBD
a_DT
PMLRAR_NN
alpha_NN
cDNA_NN
in_IN
myeloid_JJ
cells_NNS
of_IN
transgenic_JJ
mice_NNS
._.

PMLRAR_NN
alpha_NN
transgenic_JJ
mice_NNS
exhibited_VBD
impaired_JJ
neutrophil_NN
maturation_NN
early_RB
in_IN
life_NN
,_,
which_WDT
progressed_VBD
at_IN
a_DT
low_JJ
frequency_NN
over_IN
the_DT
course_NN
of_IN
several_JJ
months_NNS
to_TO
overt_JJ
APL_NN
._.

Both_CC
the_DT
preleukemic_JJ
state_NN
and_CC
the_DT
leukemia_NN
could_MD
be_VB
transplanted_VBN
to_TO
nontransgenic_JJ
mice_NNS
,_,
and_CC
the_DT
transplanted_VBN
preleukemia_NN
could_MD
progress_VB
to_TO
APL_NN
._.

The_DT
APL_NN
recapitulated_VBD
features_NNS
of_IN
the_DT
human_JJ
disease_NN
,_,
including_VBG
a_DT
response_NN
to_TO
retinoic_JJ
acid_NN
._.

Retinoic_JJ
acid_NN
caused_VBD
the_DT
leukemic_JJ
cells_NNS
to_TO
differentiate_VB
in_FW
vitro_FW
and_CC
in_FW
vivo_FW
,_,
eliciting_VBG
remissions_NNS
of_IN
both_CC
the_DT
preleukemic_JJ
state_NN
and_CC
APL_NN
in_IN
mice_NNS
._.

Our_PRP$
results_NNS
demonstrate_VBP
that_IN
PMLRAR_NN
alpha_NN
impairs_VBZ
neutrophil_NN
differentiation_NN
and_CC
initiates_VBZ
the_DT
development_NN
of_IN
APL_NN
._.

The_DT
transgenic_JJ
mice_NNS
described_VBN
here_RB
provide_VBP
an_DT
apparently_RB
accurate_JJ
model_NN
for_IN
human_JJ
APL_NN
that_WDT
includes_VBZ
clear_JJ
evidence_NN
of_IN
tumor_NN
progression_NN
._.

The_DT
model_NN
should_MD
be_VB
useful_JJ
for_IN
exploring_VBG
the_DT
molecular_JJ
pathogenesis_NN
of_IN
APL_NN
and_CC
the_DT
mechanisms_NNS
of_IN
the_DT
therapeutic_JJ
response_NN
to_TO
retinoic_JJ
acid_NN
,_,
as_RB
well_RB
as_IN
for_IN
preclinical_JJ
studies_NNS
of_IN
therapeutic_JJ
regimens_NNS
._.

